Matches in SemOpenAlex for { <https://semopenalex.org/work/W2267856035> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- W2267856035 endingPage "4698" @default.
- W2267856035 startingPage "4698" @default.
- W2267856035 abstract "4698 Background: The epidermal growth factor receptor (EGFR) is expressed in most prostate cancers. We investigated the effect of gefitinib (ZD1839), an orally active EGFR tyrosine kinase inhibitor, on the slope of changing prostate specific antigen (PSA) levels. Methods: We conducted a placebo-controlled, double blind, randomized Phase II study of gefitinib (500 mg/day) in patients with prostate cancer and hormone-independent PSA progression. To calculate sample size, the method of Schlesselman (J Chron Dis 1973; 26: 561–70) was applied; 24 patients per group were necessary to detect a change in slope of 0.25 (ie to zero slope) with 90% power using a two-sided significance level of alpha = 0.05. Asymptomatic patients with PSA progression after castration or under luteinizing hormone-releasing hormone treatment (excluding antiandrogens and recent radiotherapy) were eligible. Unblinding took place after 6 months or in the case of medical emergencies. Secondary endpoints included PSA response rate at 6 months, time to response, PSA progression, time to progression (TTP), overall survival (OS), and safety. The study was approved by regional and institutional ethical review boards. Results: All 58 patients randomized (28 to placebo and 30 to gefitinib) were evaluable for comparison of PSA slopes. Both slopes differed significantly from zero (placebo: p<0.0001; gefitinib: p<0.0023). The slopes amounted to 0.2569 for placebo and 0.2001 for gefitinib per month, translating into doubling times of 3.9 and 5.0 months (p=0.25), respectively. This study was not powered to compare changes in slope between treatment arms however, no relevant differences in progression rates, TTP, and OS were seen between arms in intention-to-treat and treatment-received analysis. Adverse events (AEs) were usually mild; CTC grade 3/4 AEs occurred in 2 patients receiving placebo and 5 receiving gefitinib (liver toxicity, diarrhea). Conclusions: Gefitinib showed modest activity in delaying PSA rise. Differences in clinical progression rates were not seen. Gefitinib was generally well tolerated. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Schering AG Schering AG Schering AG AstraZeneca Uroconsultancy BV Uroconsultancy BV" @default.
- W2267856035 created "2016-06-24" @default.
- W2267856035 creator A5041240078 @default.
- W2267856035 creator A5044653994 @default.
- W2267856035 date "2004-07-15" @default.
- W2267856035 modified "2023-10-18" @default.
- W2267856035 title "ZD1839 (gefitinib) and hormone resistant (HR) prostate cancer - final results of a double blind randomized placebo-controlled phase II study" @default.
- W2267856035 doi "https://doi.org/10.1200/jco.2004.22.90140.4698" @default.
- W2267856035 hasPublicationYear "2004" @default.
- W2267856035 type Work @default.
- W2267856035 sameAs 2267856035 @default.
- W2267856035 citedByCount "8" @default.
- W2267856035 countsByYear W22678560352012 @default.
- W2267856035 crossrefType "journal-article" @default.
- W2267856035 hasAuthorship W2267856035A5041240078 @default.
- W2267856035 hasAuthorship W2267856035A5044653994 @default.
- W2267856035 hasConcept C121608353 @default.
- W2267856035 hasConcept C126322002 @default.
- W2267856035 hasConcept C126894567 @default.
- W2267856035 hasConcept C142724271 @default.
- W2267856035 hasConcept C143998085 @default.
- W2267856035 hasConcept C168563851 @default.
- W2267856035 hasConcept C203092338 @default.
- W2267856035 hasConcept C204787440 @default.
- W2267856035 hasConcept C27081682 @default.
- W2267856035 hasConcept C2779438470 @default.
- W2267856035 hasConcept C2780192828 @default.
- W2267856035 hasConcept C2780580887 @default.
- W2267856035 hasConcept C2781406297 @default.
- W2267856035 hasConcept C71924100 @default.
- W2267856035 hasConceptScore W2267856035C121608353 @default.
- W2267856035 hasConceptScore W2267856035C126322002 @default.
- W2267856035 hasConceptScore W2267856035C126894567 @default.
- W2267856035 hasConceptScore W2267856035C142724271 @default.
- W2267856035 hasConceptScore W2267856035C143998085 @default.
- W2267856035 hasConceptScore W2267856035C168563851 @default.
- W2267856035 hasConceptScore W2267856035C203092338 @default.
- W2267856035 hasConceptScore W2267856035C204787440 @default.
- W2267856035 hasConceptScore W2267856035C27081682 @default.
- W2267856035 hasConceptScore W2267856035C2779438470 @default.
- W2267856035 hasConceptScore W2267856035C2780192828 @default.
- W2267856035 hasConceptScore W2267856035C2780580887 @default.
- W2267856035 hasConceptScore W2267856035C2781406297 @default.
- W2267856035 hasConceptScore W2267856035C71924100 @default.
- W2267856035 hasIssue "14_suppl" @default.
- W2267856035 hasLocation W22678560351 @default.
- W2267856035 hasOpenAccess W2267856035 @default.
- W2267856035 hasPrimaryLocation W22678560351 @default.
- W2267856035 hasRelatedWork W189616576 @default.
- W2267856035 hasRelatedWork W2055393917 @default.
- W2267856035 hasRelatedWork W2059622952 @default.
- W2267856035 hasRelatedWork W2074491453 @default.
- W2267856035 hasRelatedWork W2111952090 @default.
- W2267856035 hasRelatedWork W2156659229 @default.
- W2267856035 hasRelatedWork W2177170042 @default.
- W2267856035 hasRelatedWork W2607442245 @default.
- W2267856035 hasRelatedWork W2808552915 @default.
- W2267856035 hasRelatedWork W3087698600 @default.
- W2267856035 hasVolume "22" @default.
- W2267856035 isParatext "false" @default.
- W2267856035 isRetracted "false" @default.
- W2267856035 magId "2267856035" @default.
- W2267856035 workType "article" @default.